aibio
Listings ·
Gelteq closes second debt tranche, receiving $2.5 million net of discount
Shareholders approved the second tranche on June 18, 2026, and the investor now holds a $2.875 million note convertible at 93% of recent trading prices.
GELS Gelteq Limited
Gelteq (GELS) news GELS convertible notes news
Latest Gelteq news
- Debt Financing
Gelteq agrees to up to $3.5 million in convertible note financing
An institutional investor will fund up to $3.5 million in two tranches. The first note carries 7% interest, matures in eighteen months and converts at a price that cannot fall below $0.50.
- Distress
Gelteq files late notice for 20-F, says it needs more time on financials
The company expects to file its annual report for the year ended June 30, 2025 within the fifteen-day grace period.
- Listings
Gelteq signs deal to sell up to $12,000,000 of shares to Lincoln Park
Gelteq cannot sell to Lincoln Park until a resale registration statement is declared effective. The agreement caps issuance at 1,881,328 shares unless shareholders approve more or the average price reaches $1.29.
Gelteq annual financials
| Line | FY ended Jun 30, 2025 | FY ended Jun 30, 2024 |
|---|---|---|
| Revenue | A$165,645 | |
| Research and development | A$628,606 | A$276,057 |
| Net income (loss) | -A$6.6 million | -A$3.5 million |
| Cash from operations | -A$5.5 million | -A$1.1 million |
| Cash and equivalents | A$344,648 | A$24,522 |
Questions about Gelteq
Has Gelteq sold convertible notes?
Our latest story on this, dated Jul 6, 2026: "Gelteq closes second debt tranche, receiving $2.5 million net of discount". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Gelteq?
Gelteq Limited trades under the ticker GELS on NASDAQ.
Where is Gelteq listed?
Gelteq Limited is listed on NASDAQ.
What is the SEC CIK of Gelteq?
The SEC Central Index Key (CIK) for Gelteq Limited is 1920092. Its filings are on SEC EDGAR.
How many shares does Gelteq have outstanding?
10,711,059 shares as of 2024-11-13, per the cover page of its 20-F filed 2025-11-17.
Which country or territory is Gelteq listed under?
Our directory records Gelteq Limited under Australia.
What does Gelteq do?
Our directory classifies Gelteq Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Gelteq?
The ISIN recorded for Gelteq Limited is AU0000218109.
Does aibio.space cover Gelteq?
aibio.space lists Gelteq Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Gelteq incorporated?
SEC records list its state or country of incorporation as C3.
What is the latest Gelteq (GELS) stock news?
Our latest story on Gelteq, dated Jul 6, 2026: "Gelteq closes second debt tranche, receiving $2.5 million net of discount". Shareholders approved the second tranche on June 18, 2026, and the investor now holds a $2.875 million note convertible at 93% of recent trading prices. Source.
Is Gelteq in financial distress?
Our latest distress story, dated Nov 3, 2025: "Gelteq files late notice for 20-F, says it needs more time on financials". The company expects to file its annual report for the year ended June 30, 2025 within the fifteen-day grace period. Source.
Is Gelteq at risk of delisting?
Our latest listing story, dated Jul 6, 2026: "Gelteq closes second debt tranche, receiving $2.5 million net of discount". Shareholders approved the second tranche on June 18, 2026, and the investor now holds a $2.875 million note convertible at 93% of recent trading prices. Source.
Is Gelteq a smaller reporting company?
SEC records list Gelteq Limited's filer category as: Non-accelerated filer<br>Emerging growth company.
Where is Gelteq headquartered?
SEC records list its business address as LEVEL 4, SOUTH MELBOURNE VIC.
Investor discussion: Gelteq
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Stock chart
SEC filings and registration
- SEC name
- Gelteq Ltd
- CIK
- 1920092
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- GELS (Nasdaq)
- State or country of incorporation
- C3
- Fiscal year ends
- June 30
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Business address
- LEVEL 4, SOUTH MELBOURNE VIC
- Phone
- 61390873990
- Shares outstanding
- 10,711,059 as of 2024-11-13 (20-F filed 2025-11-17)
- Former names
- Gelteq Pty Ltd.
Recent filings
Listing details
- Company
- Gelteq Limited
- Ticker
- GELS
- Listing
- NASDAQ
- Country or territory
- Australia
- Business scope
- Pharmaceuticals: Major
- ISIN
- AU0000218109
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction